<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944712468628</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944712468628</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The new patent foramen ovale occluder FIGULLA in complex septal anatomy: a case series</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Baglini</surname><given-names>Roberto</given-names></name>
<aff id="aff1-1753944712468628">Department of Interventional Cardiology, IsMeTT, University of Pittsburgh European Centre, via Tricomi 1, 90100 Palermo, Italy</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Baldari</surname><given-names>Duccio</given-names></name>
<aff id="aff2-1753944712468628">Department of Interventional Cardiology, IsMeTT, University of Pittsburgh European Centre, Palermo, Italy</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Amaducci</surname><given-names>Andrea</given-names></name>
<aff id="aff3-1753944712468628">Department of Interventional Cardiology, IsMeTT, University of Pittsburgh European Centre, Palermo, Italy</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>D’Ancona</surname><given-names>Giuseppe</given-names></name>
<aff id="aff4-1753944712468628">Department of Interventional Cardiology, IsMeTT, University of Pittsburgh European Centre, Palermo, Italy</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944712468628"><email>rbaglini@ismett.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>26</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1753944712468628">
<title>Background:</title>
<p>The appropriate treatment strategy for secondary stroke prevention in patients with cryptogenic stroke and patent foramen ovale (PFO) remains challenging. The aim of this study was to describe a case series of patients with PFO and complex septal anatomy who underwent percutaneous correction using a FIGULLA (Occlutech®) septal occluder (FSO).</p>
</sec>
<sec id="section2-1753944712468628">
<title>Patients:</title>
<p>Ten consecutive patients (6 females, 4 males, mean age 41.6 ± 16.0 years, range 17–52 years; Group 1) with cryptogenetic stroke and/or transient cerebral ischemia and complex septal anatomy, as defined by intraprocedural transesophageal echocardiogram (TEE) were compared with a group of 25 patients (10 females, 15 males, mean age 43.7 ± 12.3 years; Group 2) with usual tunnel-like PFO anatomy in whom PFO was closed by an Amplatzer septal occluder (ASO; AGA®).</p>
</sec>
<sec id="section3-1753944712468628">
<title>Results:</title>
<p>No significant differences were noted between Group 1 and Group 2 for immediate success rate, residual intraprosthetic shunt at the end of the procedure, discharge, 1, 6 and 12 months follow up, number of attempts, procedure time, fluoroscopy time, or cardiac complication (atrial arrhythmias, device embolism).</p>
<p>The only significant difference was shown for delivery sheath size (11 ± 2 <italic>versus</italic> 9 ± 1 F) and incidence of local hematoma (30% <italic>versus</italic> 12 %) between Group 1 and Group 2, without any clinical consequence (need of transfusion) or increase in length of stay.</p>
</sec>
<sec id="section4-1753944712468628">
<title>Conclusion:</title>
<p>FSO shows high performance in patients with PFO and complex septal anatomy when compared with patients with PFO and uncomplicated atrial anatomy treated by ASO. Its favorable behavior is probably related to fabric features such as the total amount of metal and the presence of titanium.</p>
</sec>
</abstract>
<kwd-group>
<kwd>patent foramen ovale</kwd>
<kwd>atrial septal percutaneous closure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1753944712468628" sec-type="intro">
<title>Introduction</title>
<p>The appropriate treatment strategy for secondary stroke prevention in patients with cryptogenic stroke [<xref ref-type="bibr" rid="bibr13-1753944712468628">Ma <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr11-1753944712468628">Homma <italic>et al</italic>. 1994</xref>] and patent foramen ovale (PFO) remains challenging.</p>
<p>The clinical and anatomic risk factors associated with stroke recurrence include older age [<xref ref-type="bibr" rid="bibr13-1753944712468628">Ma <italic>et al</italic>. 2004</xref>], large PFO [<xref ref-type="bibr" rid="bibr11-1753944712468628">Homma <italic>et al</italic>. 1994</xref>; <xref ref-type="bibr" rid="bibr10-1753944712468628">Hausmann <italic>et al</italic>. 1995</xref>; <xref ref-type="bibr" rid="bibr20-1753944712468628">Stone <italic>et al</italic>. 1996</xref>; <xref ref-type="bibr" rid="bibr19-1753944712468628">Schuchlenz <italic>et al</italic>. 2000</xref>] and large right-to-left shunting [<xref ref-type="bibr" rid="bibr3-1753944712468628">De Castro <italic>et al</italic>. 2000</xref>], combined atrial septal aneurysm (ASA) [<xref ref-type="bibr" rid="bibr16-1753944712468628">Meissner <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr14-1753944712468628">Mas <italic>et al</italic>. 2001</xref>] and hypertrophic Eustachian valve (HEV) [<xref ref-type="bibr" rid="bibr15-1753944712468628">Meier, 2009</xref>]. PFO is an anatomical variant of the atrial septum, providing communication between the atrial chambers of the heart through fossa ovalis on the right side and the ostium secundum on the left side. Septum primum acts as a one-way valve allowing for blood flow from the right to left atria. This septum normally remains patent before birth and closes with the first breath [<xref ref-type="bibr" rid="bibr5-1753944712468628">Gill, 2005</xref>].</p>
<p>Autopsy studies have shown an overall PFO prevalence of 27% in the general population, decreasing with increasing age (35% and 20% in age groups less than 30 years and more than 80 years, respectively) [<xref ref-type="bibr" rid="bibr12-1753944712468628">Lechat <italic>et al</italic>. 1988</xref>; <xref ref-type="bibr" rid="bibr9-1753944712468628">Hagen <italic>et al</italic>. 1984</xref>], secondary to either selective mortality of patients with PFO with age or late spontaneous closure.</p>
<p>Transthoracic echocardiography (TTE) allows the population screening by the detection of a shunt with either color Doppler or agitated saline contrast with Valsalva maneuver [<xref ref-type="bibr" rid="bibr6-1753944712468628">Gill and Quaife, 2005</xref>; <xref ref-type="bibr" rid="bibr7-1753944712468628">Gramiak <italic>et al</italic>. 1969</xref>; <xref ref-type="bibr" rid="bibr21-1753944712468628">Woods and Patel, 2006</xref>; <xref ref-type="bibr" rid="bibr8-1753944712468628">Ha <italic>et al</italic>. 2001</xref>].</p>
<p>Transcranial Doppler (TCD) provides the detection of cerebral flow modification due to right to left shunt during Valsalva maneuver [<xref ref-type="bibr" rid="bibr4-1753944712468628">Droste <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr17-1753944712468628">Nedeltchev and Mattle, 2006</xref>].</p>
<p>Transesophageal echocardiogram (TEE) or intracardiac echocardiogram are generally used during percutaneous closure to monitor the procedures [<xref ref-type="bibr" rid="bibr15-1753944712468628">Meier, 2009</xref>].</p>
<p>The classic tunnel-like anatomy of PFO may be more complex for the presence of several associated defects such as: large defects (greater than 4 mm), ASA, HEV and septal multiple cribrosity (SMC) [<xref ref-type="bibr" rid="bibr15-1753944712468628">Meier, 2009</xref>; <xref ref-type="bibr" rid="bibr18-1753944712468628">Roelandt and Budts, 2009</xref>; <xref ref-type="bibr" rid="bibr2-1753944712468628">Butera <italic>et al</italic>. 2006</xref>].</p>
<p>The aim of this study is to describe a case series of patients with PFO and complex septal anatomy who underwent percutaneous correction by FIGULLA (Occlutech ®) septal occluder (FSO) as compared with a group of patients with usual PFO anatomy who underwent percutaneous closure by Amplatzer (AGA®) septal occluder (ASO).</p>
</sec>
<sec id="section6-1753944712468628" sec-type="methods">
<title>Patients and methods</title>
<p>Ten consecutive patients (6 females, 4 males, mean age 41.6 ± 16.0 years, range 17–52 years; Group 1) with cryptogenetic stroke and/or transient cerebral ischemia and complex septal anatomy, as defined by intraprocedural TEE, were referred to our institution for PFO percutaneous closure (<xref ref-type="table" rid="table1-1753944712468628">Table 1</xref> and <xref ref-type="fig" rid="fig1-1753944712468628">Figures 1</xref><xref ref-type="fig" rid="fig2-1753944712468628"/>–<xref ref-type="fig" rid="fig3-1753944712468628">3</xref>). They were compared with 25 patients (10 females, 15 males, mean age 43.7 ± 12.3 years; Group 2) with usual tunnel-like PFO anatomy in whom PFO was closed by an Amplatzer septal occluder (ASO; AGA®) (<xref ref-type="table" rid="table1-1753944712468628">Table 1</xref>). Diagnosis was done in all of these patients by TTE and TCD. Hypercoagulability was screened and excluded in all.</p>
<table-wrap id="table1-1753944712468628" position="float">
<label>Table 1.</label>
<caption>
<p>Patients’ anatomic and clinical features.</p>
</caption>
<graphic alternate-form-of="table1-1753944712468628" xlink:href="10.1177_1753944712468628-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Patients</th>
<th align="left">Large PFO</th>
<th align="left">HEV</th>
<th align="left">SMC</th>
<th align="left">ASA</th>
<th align="left">Neurology</th>
<th align="left">Comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>mTIA and H</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Ictus cerebri</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>mTIA</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>mTIA</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>mTIA and H</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Ictus cerebri</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>mTIA</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>mTIA and H</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Single TIA</td>
<td>Cirrhosis<xref ref-type="table-fn" rid="table-fn2-1753944712468628">*</xref></td>
</tr>
<tr>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>mTIA</td>
<td>No</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1753944712468628"><p>HEV, hypertrophy of Eustachian valve; SMC, septal multicribrosity; ASA, atrial septal aneurysm; mTIA, multiple transient ischemic attack; PFO, patent foramen ovale; H, hemicrania.</p></fn>
<fn id="table-fn2-1753944712468628">
<label>*</label>
<p>Patient in work up for liver retransplantation.</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1753944712468628" position="float">
<label>Figure 1.</label>
<caption>
<p>Atrial septal aneurysm.</p>
</caption>
<graphic xlink:href="10.1177_1753944712468628-fig1.tif"/></fig>
<fig id="fig2-1753944712468628" position="float">
<label>Figure 2.</label>
<caption>
<p>Septal multicribrosity.</p>
</caption>
<graphic xlink:href="10.1177_1753944712468628-fig2.tif"/></fig>
<fig id="fig3-1753944712468628" position="float">
<label>Figure 3.</label>
<caption>
<p>Eustachian hypertrophy.</p>
</caption>
<graphic xlink:href="10.1177_1753944712468628-fig3.tif"/></fig>
<p>All patients underwent percutaneous PFO closure under general anesthesia and orotracheal intubation. All procedural steps were monitored by TEE.</p>
<p>Complex septal anatomy was defined as the presence and/or association of the following parameters: (1) large or long defects (greater than 4 and/or 7 mm, respectively); (2) ASA; (3) HEV; (4) SMC (<xref ref-type="table" rid="table1-1753944712468628">Tables 1</xref> and <xref ref-type="table" rid="table2-1753944712468628">2</xref> and <xref ref-type="fig" rid="fig1-1753944712468628">Figures 1</xref><xref ref-type="fig" rid="fig2-1753944712468628"/>–<xref ref-type="fig" rid="fig3-1753944712468628">3</xref>).</p>
<table-wrap id="table2-1753944712468628" position="float">
<label>Table 2.</label>
<caption>
<p>Complex patent foramen ovale anatomy: definition and incidence.</p>
</caption>
<graphic alternate-form-of="table2-1753944712468628" xlink:href="10.1177_1753944712468628-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td>Septal aneurysm</td>
<td>7</td>
</tr>
<tr>
<td>Eustachian hypertrophy</td>
<td>7</td>
</tr>
<tr>
<td>Septal multicrobrisity</td>
<td>5</td>
</tr>
<tr>
<td>Large defect (more than 4 mm)</td>
<td>5</td>
</tr>
<tr>
<td>Association</td>
<td>9</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Given its conformability and elasticity, the double-layer FSO (Occlutech®) was chosen to treat these complex cases.</p>
<p>The FSO device is constructed from 0.082–0.186 mm nitinol wires that are tightly woven into two flat round disks with a 4 mm connecting waist.</p>
<p>The prosthesis is filled with a polyester patch to enhance thrombogenicity. There is only one stainless steel hub (microscrew) at the right atrial disk for cable connection (<xref ref-type="fig" rid="fig4-1753944712468628">Figure 4</xref>).</p>
<fig id="fig4-1753944712468628" position="float">
<label>Figure 4.</label>
<caption>
<p>FIGULLA device.</p>
</caption>
<graphic xlink:href="10.1177_1753944712468628-fig4.tif"/></fig>
<p>A Mullins long sheath was selected for delivery of the device, advanced over an angiographic wire to the left atrium.</p>
<p>After sheath de-airing, the device was then vigorously flushed with saline before introduction into the loading catheter. It was then engaged into the delivery sheath and advanced into the left atrium. Under fluoroscopic guidance, withdrawal of the Mullins sheath allowed the release of the left atrial disk. Then the whole system was withdrawn so that the disk engaged the septum. If the position of the left disk was satisfactory under TEE study, the right disk was extruded by pulling back the sheath.</p>
<p>The operator then pushed and pulled the loading catheter several times to confirm the stability of the device. Once the device was implanted well in the position, it was released by releasing the loader.</p>
<p>A residual shunt was considered to be present if echo-contrast showed a right to left shunt across the atrial septum during Valsalva maneuver.</p>
<p>Trivial shunt occurring across the device fabric immediately after the deployment of the device was not considered significant [<xref ref-type="bibr" rid="bibr1-1753944712468628">Butera <italic>et al</italic> 2004</xref>].</p>
<p>Cardiac complication was defined as (1) prosthesis immediate or late embolism and (2) significant atrial arrhythmias (sustained atrial tachycardia or transient atrial fibrillation).</p>
<p>All patients underwent clinical examination, electrocardiography, chest radiographs and TTE before discharge, at 1, 6 and 12 months after the procedure.</p>
<p>Antiplatelet therapy with aspirin, 5 mg/kg orally per day, was prescribed for 6 months.</p>
<sec id="section7-1753944712468628">
<title>Statistical analysis</title>
<p>All analyses were performed using SPSS version 10.0 (SPSS, Inc., Chicago, IL) statistical software. The results were expressed as the mean ± SD, unless otherwise stated. Differences between outcomes in different groups of patients were analyzed by unpaired Student’s <italic>t</italic>-test.</p>
<p>Incidences in the groups were tested for significance with the chi-squared test. A <italic>p</italic> value of 0.05 was regarded as statistically significant.</p>
</sec></sec>
<sec id="section8-1753944712468628" sec-type="results">
<title>Results</title>
<p>As FSO was used starting only from the past year, the mean clinical follow up was significantly longer in Group 2 (<xref ref-type="table" rid="table3-1753944712468628">Table 3</xref>).</p>
<table-wrap id="table3-1753944712468628" position="float">
<label>Table 3.</label>
<caption>
<p>Patients characteristics, procedure variables and follow-up.</p>
</caption>
<graphic alternate-form-of="table3-1753944712468628" xlink:href="10.1177_1753944712468628-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">FSO</th>
<th align="left">ASO</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>10</td>
<td>25</td>
<td/>
</tr>
<tr>
<td>Age (years)</td>
<td>41.6 ± 16.0</td>
<td>43.7 ± 12.3</td>
<td>ns</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>6/4</td>
<td>15/10</td>
<td>ns</td>
</tr>
<tr>
<td>Device size (mm)</td>
<td>25 ± 6</td>
<td>25 ± 9</td>
<td>ns</td>
</tr>
<tr>
<td>Delivery sheath size (F)</td>
<td>11 ± 2</td>
<td>9 ± 1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Number of attempts</td>
<td>1.3 ± 0.4</td>
<td>1.8 ± 1.0</td>
<td>ns</td>
</tr>
<tr>
<td>Procedure time (min)</td>
<td>72 ± 17</td>
<td>82 ± 16</td>
<td>ns</td>
</tr>
<tr>
<td>Fluoroscopy time (seconds)</td>
<td>240 ± 28</td>
<td>211 ± 33</td>
<td>ns</td>
</tr>
<tr>
<td>Residual shunt at procedure</td>
<td>1 (10%)</td>
<td>3 (12%)</td>
<td>ns</td>
</tr>
<tr>
<td>Residual shunt at discharge</td>
<td>1 (10%)</td>
<td>2 (8%)</td>
<td>ns</td>
</tr>
<tr>
<td>Residual shunt at 1 month</td>
<td>1</td>
<td>2</td>
<td>ns</td>
</tr>
<tr>
<td>Residual shunt at 6 months</td>
<td>1</td>
<td>2</td>
<td>ns</td>
</tr>
<tr>
<td>Residual shunt at 1 year</td>
<td>1</td>
<td>2</td>
<td>ns</td>
</tr>
<tr>
<td>Procedural complication</td>
<td>2 (20%)</td>
<td>5 (20%)</td>
<td>ns</td>
</tr>
<tr>
<td>Local hematoma</td>
<td>3 (30%)</td>
<td>3 (12)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>3 (30%)</td>
<td>8 (32%)</td>
<td>ns</td>
</tr>
<tr>
<td>Tamponade</td>
<td>0</td>
<td>0</td>
<td>ns</td>
</tr>
<tr>
<td>Prosthesis embolism</td>
<td>0</td>
<td>0</td>
<td>ns</td>
</tr>
<tr>
<td>Cerebral accident</td>
<td>0</td>
<td>0</td>
<td>ns</td>
</tr>
<tr>
<td>Follow up duration (months)</td>
<td>7.5 ± 4.2</td>
<td>19.5 ± 9.5</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1753944712468628"><p>FSO, FIGULLA septal occluder; ASO, Amplatzer septal occluder; ns, nonsignificant.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>No significant differences were noted between Group 1 and Group 2 for immediate success rate, residual intraprosthetic shunt at the end of the procedure, discharge, 1, 6 and 12 months follow up, number of attempts, procedure time, fluoroscopy time or cardiac complication (atrial arrhythmias, device embolism) (<xref ref-type="table" rid="table3-1753944712468628">Table 3</xref>).</p>
<p>The only significant difference between Group 1 and Group 2 resulted from delivery sheath size (11 ± 2 <italic>versus</italic> 9 ± 1 F) and incidence of local hematoma (30% <italic>versus</italic> 12%) (<xref ref-type="table" rid="table3-1753944712468628">Table 3</xref>), without any clinical consequence (no need of transfusion or increase in hospital stay).</p>
<p>Residual intraprosthetic or periprosthetic shunt was not significantly different between Group 1 and Group 2 at 1 year (10% and 8%, respectively) (<xref ref-type="table" rid="table3-1753944712468628">Table 3</xref>).</p>
</sec>
<sec id="section9-1753944712468628" sec-type="discussion">
<title>Discussion</title>
<p>ASO is one of the most frequently used devices for ASD and has been proven to be highly effective and safe in the early to long term. Previous reports have confirmed that transcatheter closure of ASD with the ASO not only achieved a comparable efficacy and safety with that of surgical closure but had an additional advantage of causing fewer complications, requiring a shorter hospital stay and avoidance of a permanent skin scarring.</p>
<p>The device handles very well and can be recaptured after deployment of both disks and thus can be repositioned quite easily.</p>
<p>However, there are important differences between the two devices. The ASO is made up of a nitinol wire tube that is clamped in two stainless steel hubs, one on each side of the disk. In contrast, the Occlutech FIGULLA device is individually braided, avoiding a distal clamp. This may be of potential benefit to decrease the chance of a clot formation on the left atrial disk and increases flexibility of the device. Furthermore FSO has significantly less metal and is partly made from titanium which has increased biocompatibility (less nickel content). FSO is available from the manufacturer in two configurations: the double-layer FSO and the single-layer FSO that has no nitinol wire in the left atrial disk that is made of a polyester patch with a nitinol frame. Only the first configuration was used in this study.</p>
<p>As FSO has thicker diameter nitinol wire as compared with ASO, it requires larger delivery sheaths. Although the device sizes were similar in the two groups, delivery catheter sizes were significantly larger in the FSO group in our study. ASO patients (Group 2) conversely showed significantly less incidence of local hematoma in comparison with Group 1.</p>
<p>In spite of no clinically significant hematoma-related consequence among patients of this study, ASO should thus be preferentially employed in patients with hemorrhagic diathesis.</p>
<p>FSO showed high performance in patients with complex septal anatomy and PFO, showing no difference in immediate and follow-up results when compared with ASO in patients without unfavorable anatomic features. Its conformability allowed overcoming any anatomic complexity without an increase of attempts and/or procedural times. Also in cases with HEV with a limited amount of space between fossa ovalis and Eustachian valve, no trapping of this remnant occurred during the release of the right atrial disk and in no case a repositioning of the device was needed.</p>
<p>In this study no thrombotic immediate or late complication were observed neither in FSO nor in ASO patients. However, FSO has the potential to behave as a more biocompatible device owing to the significant amount of titanium used in its construction whose resistance to the body environment is well known. This is mainly due to its protective oxide films which forms naturally in the presence of even trace amounts of any form of oxygen.</p>
<p>The film is highly adherent, insoluble and chemically nontransportable, preventing reaction with tissue. Furthermore, the modulus of elasticity of titanium participates in the favorable mechanical properties of FSO. In our opinion these characteristics make FSO the device of choice in cases of patients with hemorrhagic diathesis and contra-indication to antiplatelet therapy such as the patient number 9 of this series.</p>
</sec>
<sec id="section10-1753944712468628" sec-type="conclusions">
<title>Conclusion</title>
<p>FSO shows high performance in patients with PFO and complex septal anatomy when compared with patients with PFO and uncomplicated atrial anatomy treated using ASO. Its favorable behavior is probably related to fabric features such as the total amount of metal and the presence of titanium.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Butera</surname><given-names>G.</given-names></name>
<name><surname>Carminati</surname><given-names>M.</given-names></name>
<name><surname>Chessa</surname><given-names>M.</given-names></name>
<name><surname>Delogu</surname><given-names>A.</given-names></name>
<name><surname>Drago</surname><given-names>M.</given-names></name>
<name><surname>Piazza</surname><given-names>L.</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects</article-title>. <source>Am Heart J</source> <volume>148</volume>: <fpage>507</fpage>–<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr2-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Butera</surname><given-names>G.</given-names></name>
<name><surname>Montinaro</surname><given-names>A.</given-names></name>
<name><surname>Carminati</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The pull and push technique to deal with a redundant Eustachian valve interfering with placement of a PFO occluder</article-title>. <source>Cath Cardiov Int</source> <volume>68</volume>: <fpage>961</fpage>–<lpage>964</lpage>.</citation>
</ref>
<ref id="bibr3-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Castro</surname><given-names>S.</given-names></name>
<name><surname>Cartoni</surname><given-names>D.</given-names></name>
<name><surname>Fiorelli</surname><given-names>M.</given-names></name>
<name><surname>Rasura</surname><given-names>M.</given-names></name>
<name><surname>Anzini</surname><given-names>A.</given-names></name>
<name><surname>Zanette</surname><given-names>E.</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Morphological and functional characteristics of patent foramen ovale and their embolic implications</article-title>. <source>Stroke</source> <volume>31</volume>: <fpage>2407</fpage>–<lpage>2413</lpage>.</citation>
</ref>
<ref id="bibr4-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Droste</surname><given-names>D.</given-names></name>
<name><surname>Reisener</surname><given-names>M.</given-names></name>
<name><surname>Kemeny</surname><given-names>V.</given-names></name>
<name><surname>Dittrich</surname><given-names>R.</given-names></name>
<name><surname>Schulte-Altedorneburg</surname><given-names>G.</given-names></name>
<name><surname>Stypmann</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>1999</year>) <article-title>Contrast transcranial Doppler ultrasound in the detection of right-to-left shunts. Reproducibility, comparison of two agents, and distribution of microemboli</article-title>. <source>Stroke</source> <volume>30</volume>: <fpage>1014</fpage>–<lpage>1018</lpage>.</citation>
</ref>
<ref id="bibr5-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gill</surname><given-names>E.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2005</year>) <article-title>Definitions and pathophysiology of the patent foramen ovale: “broad overview</article-title>. <source>Cardiol Clin</source> <volume>23</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr6-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gill</surname><given-names>E.</given-names><suffix>Jr</suffix></name>
<name><surname>Quaife</surname><given-names>R.</given-names></name>
</person-group> (<year>2005</year>) <article-title>The echocardiographer and the diagnosis of patent foramen ovale</article-title>. <source>Cardiol Clin</source> <volume>23</volume>: <fpage>47</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr7-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gramiak</surname><given-names>R.</given-names></name>
<name><surname>Shah</surname><given-names>P.</given-names></name>
<name><surname>Kramer</surname><given-names>D.</given-names></name>
</person-group> (<year>1969</year>) <article-title>Ultrasound cardiography: contrast studies in anatomy and function</article-title>. <source>Radiology</source> <volume>92</volume>: <fpage>939</fpage>–<lpage>948</lpage>.</citation>
</ref>
<ref id="bibr8-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ha</surname><given-names>J.</given-names></name>
<name><surname>Shin</surname><given-names>M.</given-names></name>
<name><surname>Kang</surname><given-names>S.</given-names></name>
<name><surname>Pyun</surname><given-names>W.</given-names></name>
<name><surname>Jang</surname><given-names>K.</given-names></name>
<name><surname>Byun</surname><given-names>K.</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Enhanced detection of right-to-left shunt through patent foramen ovale by transthoracic contrast echocardiography using harmonic imaging</article-title>. <source>Am J Cardiol</source> <volume>87</volume>: <fpage>669</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr9-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagen</surname><given-names>P.</given-names></name>
<name><surname>Scholz</surname><given-names>D.</given-names></name>
<name><surname>Edwards</surname><given-names>W.</given-names></name>
</person-group> (<year>1984</year>) <article-title>Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts</article-title>. <source>Mayo Clin Proc</source> <volume>59</volume>: <fpage>17</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr10-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hausmann</surname><given-names>D.</given-names></name>
<name><surname>Mugge</surname><given-names>A.</given-names></name>
<name><surname>Daniel</surname><given-names>W.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Identification of patent foramen ovale permitting paradoxic embolism</article-title>. <source>J Am Coll Cardiol</source> <volume>26</volume>: <fpage>1030</fpage>–<lpage>1038</lpage>.</citation>
</ref>
<ref id="bibr11-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>S.</given-names></name>
<name><surname>Di Tullio</surname><given-names>M.</given-names></name>
<name><surname>Sacco</surname><given-names>R.</given-names></name>
<name><surname>Mihalatos</surname><given-names>D.</given-names></name>
<name><surname>Li Mandri</surname><given-names>G.</given-names></name>
<name><surname>Mohr</surname><given-names>J.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study</article-title>. <source>Stroke</source> <volume>25</volume>: <fpage>582</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr12-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lechat</surname><given-names>P.</given-names></name>
<name><surname>Mas</surname><given-names>J.</given-names></name>
<name><surname>Lascault</surname><given-names>G.</given-names></name>
<name><surname>Loron</surname><given-names>P.</given-names></name>
<name><surname>Theard</surname><given-names>M.</given-names></name>
<name><surname>Klimczac</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>1988</year>) <article-title>Prevalence of patent foramen ovale in patients with stroke</article-title>. <source>N Engl J Med</source> <volume>318</volume>: <fpage>1148</fpage>–<lpage>1152</lpage>.</citation>
</ref>
<ref id="bibr13-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Di Tullio</surname><given-names>M.</given-names></name>
<name><surname>Sacco</surname><given-names>R.</given-names></name>
<name><surname>Sciacca</surname><given-names>R.</given-names></name>
<name><surname>Mohr</surname><given-names>J.</given-names></name>
</person-group> <collab>PICSS HomInvestigators</collab> (<year>2004</year>) <article-title>Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale</article-title>. <source>Stroke</source> <volume>35</volume>: <fpage>2145</fpage>–<lpage>2149</lpage>.</citation>
</ref>
<ref id="bibr14-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mas</surname><given-names>J.</given-names></name>
<name><surname>Arquizan</surname><given-names>C.</given-names></name>
<name><surname>Lamy</surname><given-names>C.</given-names></name>
<name><surname>Zuber</surname><given-names>M.</given-names></name>
<name><surname>Cabanes</surname><given-names>L.</given-names></name>
<name><surname>Derumeaux</surname><given-names>J.</given-names></name>
<etal/></person-group>. <collab>for the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group</collab> (<year>2001</year>) <article-title>Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both</article-title>. <source>N Engl J Med</source> <volume>345</volume>: <fpage>1740</fpage>–<lpage>1746</lpage>.</citation>
</ref>
<ref id="bibr15-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meier</surname><given-names>B.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Catheter-based closure of the patent foramen ovale</article-title>. <source>Circulation</source> <volume>120</volume>: <fpage>1837</fpage>–<lpage>1841</lpage>.</citation>
</ref>
<ref id="bibr16-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meissner</surname><given-names>I.</given-names></name>
<name><surname>Khandheria</surname><given-names>B.</given-names></name>
<name><surname>Heit</surname><given-names>J.</given-names></name>
<name><surname>Petty</surname><given-names>G.</given-names></name>
<name><surname>Sheps</surname><given-names>S.</given-names></name>
<name><surname>Schwartz</surname><given-names>G.</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study</article-title>. <source>J Am Coll Cardiol</source> <volume>47</volume>: <fpage>440</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr17-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nedeltchev</surname><given-names>K.</given-names></name>
<name><surname>Mattle</surname><given-names>H.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Contrast-enhanced transcranial Doppler ultrasound for diagnosis of patent foramen ovale</article-title>. <source>Front Neurol Neurosci</source> <volume>21</volume>: <fpage>206</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr18-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roelandt</surname><given-names>P.</given-names></name>
<name><surname>Budts</surname><given-names>W.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Eustachian valve interfering with transcatheter closure of patent foramen ovale</article-title>. <source>Eur J Echocardiogr</source> <volume>9</volume>: <fpage>158</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr19-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schuchlenz</surname><given-names>H.</given-names></name>
<name><surname>Weihs</surname><given-names>W.</given-names></name>
<name><surname>Horner</surname><given-names>S.</given-names></name>
<name><surname>Quehenberger</surname><given-names>F.</given-names></name>
</person-group> (<year>2000</year>) <article-title>The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events</article-title>. <source>Am J Med</source> <volume>109</volume>: <fpage>456</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr20-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stone</surname><given-names>D.</given-names></name>
<name><surname>Godard</surname><given-names>J.</given-names></name>
<name><surname>Corretti</surname><given-names>M.</given-names></name>
<name><surname>Kittner</surname><given-names>S.</given-names></name>
<name><surname>Sample</surname><given-names>C.</given-names></name>
<name><surname>Price</surname><given-names>T.</given-names></name>
<etal/></person-group>. (<year>1996</year>) <article-title>Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events</article-title>. <source>Am Heart J</source> <volume>131</volume>: <fpage>158</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr21-1753944712468628">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woods</surname><given-names>T.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>A critical review of patent foramen ovale detection using saline contrast echocardiography: when bubbles lie</article-title>. <source>J Am Soc Echocardiogr</source> <volume>19</volume>: <fpage>215</fpage>–<lpage>222</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>